Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products

RESEARCH TRIANGLE PARK, N.C. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, today announced that it has

PTAB Institutes Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent and Denies Institution on ‘066 Patent for Tyvaso® RESEARCH TRIANGLE PARK, N.C. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company

Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care RESEARCH TRIANGLE PARK, N.C. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and

Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020 RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization

RESEARCH TRIANGLE PARK, N.C. , Aug. 28, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, today announced that it has

Steven Bariahtaris Appointed Interim Chief Financial Officer RESEARCH TRIANGLE PARK, N.C. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its

Received FDA Acceptance of LIQ861 NDA for Review Reported Final Safety and Tolerability Results for LIQ861 INSPIRE Trial Appointed Tushar Shah , M.D. as Chief Medical Officer Announced Definitive Agreement to Acquire RareGen, LLC Completed Public Offering of Common Stock Company to Host Webcast and

RESEARCH TRIANGLE PARK, N.C. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal

New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL) RESEARCH TRIANGLE PARK, N.C. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.